The drug is sold in about 40 countries, including Europe. A company spokeswoman said Friday it will take a few months to implement the suspension worldwide.
Merck said last month initial results from a big, late-stage study showed that adding Tredaptive to traditional statin therapy failed to lower the risk of heart attack, stroke and related problems. The drugmaker said then that doctors should stop prescribing Tredaptive to new patients.
Results also showed that patients taking the cholesterol combination pill were more likely to suffer some serious, non-fatal adverse events that fall into several broad categories: blood and lymphatic, gastrointestinal, infections, metabolism, musculoskeletal, respiratory and skin. The company said researchers are still analyzing the adverse events, and it offered no additional details.
Merck said it made its decision based in part on a European Medicine Agency committee recommendation.
Statins are a class of drugs that have long been used to lower levels of LDL, or “bad,” cholesterol and slightly raise levels of HDL, or “good,” cholesterol in the blood. Tredaptive is a combination pill made up of niacin, which boosts good cholesterol, and laropiprant, which reduces the facial flushing caused by niacin.
The drug isn't a major product for Merck. It posted only $13 million in sales during the first three quarters of 2012.
Shares of Merck rose 32 cents to $43.10 in late morning trading Friday. They have traded in a 52-week range of $36.91 to $48.